Leucovorin
Brand Name:
Manufacturer:
Indication
Indication:
Indicated as a modulating agent used in combination with fluorouracil-based chemotherapy for colorectal cancer in both adjuvant and metastatic settings. It is most commonly administered with 5-fluorouracil as part of regimens such as FOLFOX and FOLFIRI to enhance the antitumour activity of fluorouracil in the treatment of stage III colon cancer after surgical resection and metastatic colorectal cancer (mCRC). Leucovorin does not have independent anticancer activity in colorectal cancer but is an essential component of standard combination chemotherapy regimens widely used across Canada.
Specific CRC Subtype: None
Stage: II, III, IV
Therapy Line: First-line, Third-line or later
Health Canada Approval: Approved
pCPA Negotiation Status:
Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan), YU (Yukon)
New Search
